Thomas J Scriba1, Andrew Fiore-Gartland2, Adam Penn-Nicholson1, Humphrey Mulenga1, Stanley Kimbung Mbandi1, Bhavesh Borate2, Simon C Mendelsohn1, Katie Hadley1, Chris Hikuam1, Masooda Kaskar1, Munyaradzi Musvosvi1, Nicole Bilek1, Steven Self2, Tom Sumner3, Richard G White3, Mzwandile Erasmus1, Lungisa Jaxa1, Rodney Raphela1, Craig Innes4, William Brumskine4, Andriëtte Hiemstra5, Stephanus T Malherbe5, Razia Hassan-Moosa6, Michèle Tameris1, Gerhard Walzl5, Kogieleum Naidoo6, Gavin Churchyard7, Mark Hatherill8. 1. South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. 2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. TB Modelling Group, TB Centre, Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. 4. The Aurum Institute, Johannesburg, South Africa. 5. DST/NRF Centre of Excellence for Biomedical TB Research and South African Medical Research Council Centre for TB Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Parow, South Africa. 6. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. 7. The Aurum Institute, Johannesburg, South Africa; School of Public Health, University of Witwatersrand, Johannesburg, South Africa. 8. South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. Electronic address: mark.hatherill@uct.ac.za.
Abstract
BACKGROUND: Targeted preventive therapy for individuals at highest risk of incident tuberculosis might impact the epidemic by interrupting transmission. We tested performance of a transcriptomic signature of tuberculosis (RISK11) and efficacy of signature-guided preventive therapy in parallel, using a hybrid three-group study design. METHODS: Adult volunteers aged 18-59 years were recruited at five geographically distinct communities in South Africa. Whole blood was sampled for RISK11 by quantitative RT-PCR assay from eligible volunteers without HIV, recent previous tuberculosis (ie, <3 years before screening), or comorbidities at screening. RISK11-positive participants were block randomised (1:2; block size 15) to once-weekly, directly-observed, open-label isoniazid and rifapentine for 12 weeks (ie, RISK11 positive and 3HP positive), or no treatment (ie, RISK11 positive and 3HP negative). A subset of eligible RISK11-negative volunteers were randomly assigned to no treatment (ie, RISK11 negative and 3HP negative). Diagnostic discrimination of prevalent tuberculosis was tested in all participants at baseline. Thereafter, prognostic discrimination of incident tuberculosis was tested in the untreated RISK11-positive versus RISK11-negative groups, and treatment efficacy in the 3HP-treated versus untreated RISK11-positive groups, during active surveillance through 15 months. The primary endpoint was microbiologically confirmed pulmonary tuberculosis. The primary outcome measures were risk ratio [RR] for tuberculosis of RISK11-positive to RISK11-negative participants, and treatment efficacy. This trial is registered with ClinicalTrials.gov, NCT02735590. FINDINGS: 20 207 volunteers were screened, and 2923 participants were enrolled, including RISK11-positive participants randomly assigned to 3HP (n=375) or no 3HP (n=764), and 1784 RISK11-negative participants. Cumulative probability of prevalent or incident tuberculosis disease was 0·066 (95% CI 0·049 to 0·084) in RISK11-positive (3HP negative) participants and 0·018 (0·011 to 0·025) in RISK11-negative participants (RR 3·69, 95% CI 2·25-6·05) over 15 months. Tuberculosis prevalence was 47 (4·1%) of 1139 versus 14 (0·78%) of 1984 in RISK11-positive compared with RISK11-negative participants, respectively (diagnostic RR 5·13, 95% CI 2·93 to 9·43). Tuberculosis incidence over 15 months was 2·09 (95% CI 0·97 to 3·19) vs 0·80 (0·30 to 1·30) per 100 person years in RISK11-positive (3HP-negative) participants compared with RISK11-negative participants (cumulative incidence ratio 2·6, 95% CI 1·2 to 5·9). Serious adverse events related to 3HP included one hospitalisation for seizures (unintentional isoniazid overdose) and one death of unknown cause (possibly temporally related). Tuberculosis incidence over 15 months was 1·94 (95% CI 0·35 to 3·50) versus 2·09 (95% CI 0·97 to 3·19) per 100 person-years in 3HP-treated RISK11-positive participants compared with untreated RISK11-positive participants (efficacy 7·0%, 95% CI -145 to 65). INTERPRETATION: The RISK11 signature discriminated between individuals with prevalent tuberculosis, or progression to incident tuberculosis, and individuals who remained healthy, but provision of 3HP to signature-positive individuals after exclusion of baseline disease did not reduce progression to tuberculosis over 15 months. FUNDING: Bill and Melinda Gates Foundation, South African Medical Research Council.
BACKGROUND: Targeted preventive therapy for individuals at highest risk of incident tuberculosis might impact the epidemic by interrupting transmission. We tested performance of a transcriptomic signature of tuberculosis (RISK11) and efficacy of signature-guided preventive therapy in parallel, using a hybrid three-group study design. METHODS: Adult volunteers aged 18-59 years were recruited at five geographically distinct communities in South Africa. Whole blood was sampled for RISK11 by quantitative RT-PCR assay from eligible volunteers without HIV, recent previous tuberculosis (ie, <3 years before screening), or comorbidities at screening. RISK11-positive participants were block randomised (1:2; block size 15) to once-weekly, directly-observed, open-label isoniazid and rifapentine for 12 weeks (ie, RISK11 positive and 3HP positive), or no treatment (ie, RISK11 positive and 3HP negative). A subset of eligible RISK11-negative volunteers were randomly assigned to no treatment (ie, RISK11 negative and 3HP negative). Diagnostic discrimination of prevalent tuberculosis was tested in all participants at baseline. Thereafter, prognostic discrimination of incident tuberculosis was tested in the untreated RISK11-positive versus RISK11-negative groups, and treatment efficacy in the 3HP-treated versus untreated RISK11-positive groups, during active surveillance through 15 months. The primary endpoint was microbiologically confirmed pulmonary tuberculosis. The primary outcome measures were risk ratio [RR] for tuberculosis of RISK11-positive to RISK11-negative participants, and treatment efficacy. This trial is registered with ClinicalTrials.gov, NCT02735590. FINDINGS: 20 207 volunteers were screened, and 2923 participants were enrolled, including RISK11-positive participants randomly assigned to 3HP (n=375) or no 3HP (n=764), and 1784 RISK11-negative participants. Cumulative probability of prevalent or incident tuberculosis disease was 0·066 (95% CI 0·049 to 0·084) in RISK11-positive (3HP negative) participants and 0·018 (0·011 to 0·025) in RISK11-negative participants (RR 3·69, 95% CI 2·25-6·05) over 15 months. Tuberculosis prevalence was 47 (4·1%) of 1139 versus 14 (0·78%) of 1984 in RISK11-positive compared with RISK11-negative participants, respectively (diagnostic RR 5·13, 95% CI 2·93 to 9·43). Tuberculosis incidence over 15 months was 2·09 (95% CI 0·97 to 3·19) vs 0·80 (0·30 to 1·30) per 100 person years in RISK11-positive (3HP-negative) participants compared with RISK11-negative participants (cumulative incidence ratio 2·6, 95% CI 1·2 to 5·9). Serious adverse events related to 3HP included one hospitalisation for seizures (unintentional isoniazid overdose) and one death of unknown cause (possibly temporally related). Tuberculosis incidence over 15 months was 1·94 (95% CI 0·35 to 3·50) versus 2·09 (95% CI 0·97 to 3·19) per 100 person-years in 3HP-treated RISK11-positive participants compared with untreated RISK11-positive participants (efficacy 7·0%, 95% CI -145 to 65). INTERPRETATION: The RISK11 signature discriminated between individuals with prevalent tuberculosis, or progression to incident tuberculosis, and individuals who remained healthy, but provision of 3HP to signature-positive individuals after exclusion of baseline disease did not reduce progression to tuberculosis over 15 months. FUNDING: Bill and Melinda Gates Foundation, South African Medical Research Council.
Authors: Fatoumatta Darboe; Stanley Kimbung Mbandi; Ethan G Thompson; Michelle Fisher; Miguel Rodo; Michele van Rooyen; Elizabeth Filander; Nicole Bilek; Simbarashe Mabwe; Mark Hatherill; Daniel E Zak; Adam Penn-Nicholson; Thomas J Scriba Journal: Tuberculosis (Edinb) Date: 2017-11-06 Impact factor: 3.131
Authors: Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson Journal: N Engl J Med Date: 2011-12-08 Impact factor: 91.245
Authors: Edine W Tiemersma; Marieke J van der Werf; Martien W Borgdorff; Brian G Williams; Nico J D Nagelkerke Journal: PLoS One Date: 2011-04-04 Impact factor: 3.240
Authors: Fatoumatta Darboe; Stanley Kimbung Mbandi; Kogieleum Naidoo; Nonhlanhla Yende-Zuma; Lara Lewis; Ethan G Thompson; Fergal J Duffy; Michelle Fisher; Elizabeth Filander; Michele van Rooyen; Nicole Bilek; Simbarashe Mabwe; Lyle R McKinnon; Novel Chegou; Andre Loxton; Gerhard Walzl; Gerard Tromp; Nesri Padayatchi; Dhineshree Govender; Mark Hatherill; Salim Abdool Karim; Daniel E Zak; Adam Penn-Nicholson; Thomas J Scriba Journal: Front Microbiol Date: 2019-06-26 Impact factor: 5.640
Authors: Andrew Fiore-Gartland; Lindsay N Carpp; Kogieleum Naidoo; Ethan Thompson; Daniel E Zak; Steve Self; Gavin Churchyard; Gerhard Walzl; Adam Penn-Nicholson; Thomas J Scriba; Mark Hatherill Journal: Tuberculosis (Edinb) Date: 2017-11-22 Impact factor: 3.131
Authors: Carolin T Turner; Rishi K Gupta; Evdokia Tsaliki; Jennifer K Roe; Prasenjit Mondal; Georgina R Nyawo; Zaida Palmer; Robert F Miller; Byron Wp Reeve; Grant Theron; Mahdad Noursadeghi Journal: Lancet Respir Med Date: 2020-03-13 Impact factor: 30.700
Authors: Rishi K Gupta; Carolin T Turner; Cristina Venturini; Hanif Esmail; Molebogeng X Rangaka; Andrew Copas; Marc Lipman; Ibrahim Abubakar; Mahdad Noursadeghi Journal: Lancet Respir Med Date: 2020-01-17 Impact factor: 30.700
Authors: Julie G Burel; Akul Singhania; Paige Dubelko; Julius Muller; Rachel Tanner; Eneida Parizotto; Martin Dedicoat; Thomas E Fletcher; James Dunbar; Adam F Cunningham; Cecilia S Lindestam Arlehamn; Donald G Catanzaro; Antonino Catanzaro; Timothy Rodwell; Helen McShane; Matthew K O'Shea; Bjoern Peters Journal: Tuberculosis (Edinb) Date: 2021-09-14 Impact factor: 3.131
Authors: Ethan D Valinetz; Daniel Matemo; Jill K Gersh; Lara L Joudeh; Simon C Mendelsohn; Thomas J Scriba; Mark Hatherill; John Kinuthia; Anna Wald; Gerard A Cangelosi; Ruanne V Barnabas; Thomas R Hawn; David J Horne Journal: AIDS Date: 2022-05-25 Impact factor: 4.632
Authors: Jan Heyckendorf; Sophia B Georghiou; Nicole Frahm; Norbert Heinrich; Irina Kontsevaya; Maja Reimann; David Holtzman; Marjorie Imperial; Daniela M Cirillo; Stephen H Gillespie; Morten Ruhwald Journal: Clin Microbiol Rev Date: 2022-03-21 Impact factor: 50.129
Authors: Giovanni Battista Migliori; Catherine W M Ong; Linda Petrone; Lia D'Ambrosio; Rosella Centis; Delia Goletti Journal: Breathe (Sheff) Date: 2021-09
Authors: Tara Carney; Jennifer A Rooney; Nandi Niemand; Bronwyn Myers; Danie Theron; Robin Wood; Laura F White; Christina S Meade; Novel N Chegou; Elizabeth Ragan; Gerhard Walzl; Robert Horsburgh; Robin M Warren; Karen R Jacobson Journal: PLoS One Date: 2022-02-15 Impact factor: 3.752